Home › Gallbladder Cancer
Gallbladder Cancer clinical trials recruiting in the U.S.
14 studies for Gallbladder Cancer are recruiting participants at sites across the United States.
Gallbladder cancer is difficult to diagnose because there are no symptoms in its early stages. Read about tests, treatment options and prognosis.
Cities with the most studies
- Cleveland, OH4 studies
- New York City, NY4 studies
- Baldwin Park, CA4 studies
- Nashville, TN4 studies
- Omaha, NE3 studies
- Seattle, WA3 studies
- Oklahoma City, OK3 studies
- Dallas, TX3 studies
- Louisville, KY3 studies
- Detroit, MI3 studies
- Boston, MA3 studies
- Birmingham, AL3 studies
- Houston, TX3 studies
- Portland, OR3 studies
- Los Angeles, CA3 studies
- Pittsburgh, PA3 studies
- Philadelphia, PA3 studies
By state
- Alabama3 studies
- California9 studies
- Colorado4 studies
- Connecticut3 studies
- Florida8 studies
- Illinois4 studies
- Kentucky3 studies
- Massachusetts4 studies
- Michigan4 studies
- Minnesota3 studies
- Nebraska3 studies
- New York5 studies
- North Carolina4 studies
- Ohio7 studies
- Oklahoma3 studies
- Oregon3 studies
- Pennsylvania4 studies
- Tennessee4 studies
- Texas5 studies
- Washington3 studies
- Wisconsin3 studies
Recently updated studies
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07221253DESTINY-PANTUMOUR04
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Sep 22, 2026 · NCT07146646The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06282575Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07780838A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06760819Distance-Based Exercise to Preserve Function and Prevent Disability
Recruiting
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07059884Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05285358Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Jul 13, 2026 · NCT05000294Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Recruiting
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT06101277A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT07265674Integrated Cancer Repository for Cancer Research
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Recruiting
Ages 18 to 99 · All sexes · Updated Feb 20, 2026 · NCT04907643From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.